Cargando…

Elevated Inflammatory Plasma Biomarkers in Patients With Fabry Disease: A Critical Link to Heart Failure With Preserved Ejection Fraction

BACKGROUND: Because systemic inflammation and endothelial dysfunction lead to heart failure with preserved ejection fraction, we characterized plasma levels of inflammatory and cardiac remodeling biomarkers in patients with Fabry disease (FD). METHODS AND RESULTS: Plasma biomarkers were studied in m...

Descripción completa

Detalles Bibliográficos
Autores principales: Yogasundaram, Haran, Nikhanj, Anish, Putko, Brendan N., Boutin, Michel, Jain‐Ghai, Shailly, Khan, Aneal, Auray‐Blais, Christiane, West, Michael L., Oudit, Gavin Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6404196/
https://www.ncbi.nlm.nih.gov/pubmed/30571380
http://dx.doi.org/10.1161/JAHA.118.009098
_version_ 1783400822340583424
author Yogasundaram, Haran
Nikhanj, Anish
Putko, Brendan N.
Boutin, Michel
Jain‐Ghai, Shailly
Khan, Aneal
Auray‐Blais, Christiane
West, Michael L.
Oudit, Gavin Y.
author_facet Yogasundaram, Haran
Nikhanj, Anish
Putko, Brendan N.
Boutin, Michel
Jain‐Ghai, Shailly
Khan, Aneal
Auray‐Blais, Christiane
West, Michael L.
Oudit, Gavin Y.
author_sort Yogasundaram, Haran
collection PubMed
description BACKGROUND: Because systemic inflammation and endothelial dysfunction lead to heart failure with preserved ejection fraction, we characterized plasma levels of inflammatory and cardiac remodeling biomarkers in patients with Fabry disease (FD). METHODS AND RESULTS: Plasma biomarkers were studied in multicenter cohorts of patients with FD (n=68) and healthy controls (n=40). Plasma levels of the following markers of inflammation and cardiac remodeling were determined: tumor necrosis factor (TNF), TNF receptor 1 (TNFR1) and 2 (TNFR2), interleukin‐6, matrix metalloprotease‐2 (MMP‐2), MMP‐8, MMP‐9, galectin‐1, galectin‐3, B‐type natriuretic peptide (BNP), midregional pro–atrial natriuretic peptide (MR‐proANP), and globotriaosylsphingosine. Clinical profile, cardiac magnetic resonance imaging, and echocardiogram were reviewed and correlated with biomarkers. Patients with FD had elevated plasma levels of BNP, MR‐proANP, MMP‐2, MMP‐9, TNF, TNFR1, TNFR2, interleukin‐6, galectin‐1, globotriaosylsphingosine, and analogues. Plasma TNFR2, TNF, interleukin‐6, MMP‐2, and globotriaosylsphingosine were elevated in FD patients with left ventricular hypertrophy, whereas diastolic dysfunction correlated with higher BNP, MR‐proANP, and MMP‐2 levels. Patients with late gadolinium enhancement on cardiac magnetic resonance imaging had greater levels of BNP, MR‐proANP, TNFR1, TNFR2, and MMP‐2. Plasma BNP, MR‐proANP, MMP‐2, MMP‐8, TNF, TNFR1, TNFR2, galectin‐1, and galectin‐3 were elevated in patients with renal dysfunction. Patients undergoing enzyme replacement therapy who have more severe disease had higher MMP‐2, TNF, TNFR1, TNFR2, and globotriaosylsphingosine analogue levels. CONCLUSIONS: Inflammatory and cardiac remodeling biomarkers are elevated in FD patients and correlate with disease progression. These features are consistent with a phenotype dominated by heart failure with preserved ejection fraction and suggest a key pathogenic role of systemic inflammation in FD.
format Online
Article
Text
id pubmed-6404196
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-64041962019-03-18 Elevated Inflammatory Plasma Biomarkers in Patients With Fabry Disease: A Critical Link to Heart Failure With Preserved Ejection Fraction Yogasundaram, Haran Nikhanj, Anish Putko, Brendan N. Boutin, Michel Jain‐Ghai, Shailly Khan, Aneal Auray‐Blais, Christiane West, Michael L. Oudit, Gavin Y. J Am Heart Assoc Original Research BACKGROUND: Because systemic inflammation and endothelial dysfunction lead to heart failure with preserved ejection fraction, we characterized plasma levels of inflammatory and cardiac remodeling biomarkers in patients with Fabry disease (FD). METHODS AND RESULTS: Plasma biomarkers were studied in multicenter cohorts of patients with FD (n=68) and healthy controls (n=40). Plasma levels of the following markers of inflammation and cardiac remodeling were determined: tumor necrosis factor (TNF), TNF receptor 1 (TNFR1) and 2 (TNFR2), interleukin‐6, matrix metalloprotease‐2 (MMP‐2), MMP‐8, MMP‐9, galectin‐1, galectin‐3, B‐type natriuretic peptide (BNP), midregional pro–atrial natriuretic peptide (MR‐proANP), and globotriaosylsphingosine. Clinical profile, cardiac magnetic resonance imaging, and echocardiogram were reviewed and correlated with biomarkers. Patients with FD had elevated plasma levels of BNP, MR‐proANP, MMP‐2, MMP‐9, TNF, TNFR1, TNFR2, interleukin‐6, galectin‐1, globotriaosylsphingosine, and analogues. Plasma TNFR2, TNF, interleukin‐6, MMP‐2, and globotriaosylsphingosine were elevated in FD patients with left ventricular hypertrophy, whereas diastolic dysfunction correlated with higher BNP, MR‐proANP, and MMP‐2 levels. Patients with late gadolinium enhancement on cardiac magnetic resonance imaging had greater levels of BNP, MR‐proANP, TNFR1, TNFR2, and MMP‐2. Plasma BNP, MR‐proANP, MMP‐2, MMP‐8, TNF, TNFR1, TNFR2, galectin‐1, and galectin‐3 were elevated in patients with renal dysfunction. Patients undergoing enzyme replacement therapy who have more severe disease had higher MMP‐2, TNF, TNFR1, TNFR2, and globotriaosylsphingosine analogue levels. CONCLUSIONS: Inflammatory and cardiac remodeling biomarkers are elevated in FD patients and correlate with disease progression. These features are consistent with a phenotype dominated by heart failure with preserved ejection fraction and suggest a key pathogenic role of systemic inflammation in FD. John Wiley and Sons Inc. 2018-11-02 /pmc/articles/PMC6404196/ /pubmed/30571380 http://dx.doi.org/10.1161/JAHA.118.009098 Text en © 2018 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Research
Yogasundaram, Haran
Nikhanj, Anish
Putko, Brendan N.
Boutin, Michel
Jain‐Ghai, Shailly
Khan, Aneal
Auray‐Blais, Christiane
West, Michael L.
Oudit, Gavin Y.
Elevated Inflammatory Plasma Biomarkers in Patients With Fabry Disease: A Critical Link to Heart Failure With Preserved Ejection Fraction
title Elevated Inflammatory Plasma Biomarkers in Patients With Fabry Disease: A Critical Link to Heart Failure With Preserved Ejection Fraction
title_full Elevated Inflammatory Plasma Biomarkers in Patients With Fabry Disease: A Critical Link to Heart Failure With Preserved Ejection Fraction
title_fullStr Elevated Inflammatory Plasma Biomarkers in Patients With Fabry Disease: A Critical Link to Heart Failure With Preserved Ejection Fraction
title_full_unstemmed Elevated Inflammatory Plasma Biomarkers in Patients With Fabry Disease: A Critical Link to Heart Failure With Preserved Ejection Fraction
title_short Elevated Inflammatory Plasma Biomarkers in Patients With Fabry Disease: A Critical Link to Heart Failure With Preserved Ejection Fraction
title_sort elevated inflammatory plasma biomarkers in patients with fabry disease: a critical link to heart failure with preserved ejection fraction
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6404196/
https://www.ncbi.nlm.nih.gov/pubmed/30571380
http://dx.doi.org/10.1161/JAHA.118.009098
work_keys_str_mv AT yogasundaramharan elevatedinflammatoryplasmabiomarkersinpatientswithfabrydiseaseacriticallinktoheartfailurewithpreservedejectionfraction
AT nikhanjanish elevatedinflammatoryplasmabiomarkersinpatientswithfabrydiseaseacriticallinktoheartfailurewithpreservedejectionfraction
AT putkobrendann elevatedinflammatoryplasmabiomarkersinpatientswithfabrydiseaseacriticallinktoheartfailurewithpreservedejectionfraction
AT boutinmichel elevatedinflammatoryplasmabiomarkersinpatientswithfabrydiseaseacriticallinktoheartfailurewithpreservedejectionfraction
AT jainghaishailly elevatedinflammatoryplasmabiomarkersinpatientswithfabrydiseaseacriticallinktoheartfailurewithpreservedejectionfraction
AT khananeal elevatedinflammatoryplasmabiomarkersinpatientswithfabrydiseaseacriticallinktoheartfailurewithpreservedejectionfraction
AT aurayblaischristiane elevatedinflammatoryplasmabiomarkersinpatientswithfabrydiseaseacriticallinktoheartfailurewithpreservedejectionfraction
AT westmichaell elevatedinflammatoryplasmabiomarkersinpatientswithfabrydiseaseacriticallinktoheartfailurewithpreservedejectionfraction
AT ouditgaviny elevatedinflammatoryplasmabiomarkersinpatientswithfabrydiseaseacriticallinktoheartfailurewithpreservedejectionfraction